{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T01:39:11Z","timestamp":1791855551855,"version":"4.3.4"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"},{"start":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T00:00:00Z","timestamp":1657843200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","award":["Investigator Grant"],"award-info":[{"award-number":["Investigator Grant"]}],"id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","award":["Investigator Grant"],"award-info":[{"award-number":["Investigator Grant"]}],"id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The pathogenesis of pityriasis rubra pilaris (PRP) is not completely understood, but interleukin (IL)-17 has been shown to play a critical role. There are no reliable immunomodulatory agents to treat PRP. We conducted an open-label, single-arm clinical trial of secukinumab, a monoclonal antibody that inhibits IL-17A, for the treatment of PRP.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To evaluate the clinical efficacy of secukinumab and define the transcriptomic landscape of PRP and its response to IL-17A blockade.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Twelve patients with PRP were recruited for an open-label trial of secukinumab. Patients received a 24-week course of secukinumab. The primary endpoint was a \u2265 75% reduction in Psoriasis Area and Severity Index (PASI 75) from baseline to week 28. Secondary endpoints included PASI 90, change in Physician\u2019s Global Assessment (PGA), and change in Dermatology Life Quality Index (DLQI). RNA sequencing was performed on lesional and nonlesional skin biopsies obtained at baseline and week 2. Sample groups were compared to identify differential gene expression and pathway enrichment. This trial was registered with ClinicalTrials.gov: \u2018Cosentyx (secukinumab) for the treatment of adult onset pityriasis rubra pilaris\u2019 \u2013 NCT03342573.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>At week 28, six of 11 patients (55%) achieved PASI 75, and three patients (27%) achieved PASI 90. PGA (P = 0.008) and DLQI scores (P = 0.010) showed significant improvement with treatment. No serious treatment-related adverse events were encountered. Treatment with secukinumab normalized transcriptional differences between lesional and nonlesional skin. Transcriptomic data from nonresponsive patients suggest that overactivity of innate immune pathways may be driving resistance to secukinumab.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Secukinumab appears to be an effective treatment for PRP and warrants further investigation. PRP is a transcriptionally heterogeneous disease, reflecting its variable response to therapy. Agents targeting other IL-17 isoforms and innate immune mediators should be considered for future clinical trials.<\/jats:p>\n                  <jats:p>What is already known about this topic? \u00a0The pathogenesis of pityriasis rubra pilaris is incompletely understood. Successful treatment has been reported with a variety of immunomodulatory agents, but disease is often refractory to therapy.Interleukin (IL)-17 is thought to drive keratinocyte proliferation and vascular dysfunction in this disease.A previous trial demonstrated efficacy of the anti-IL-17A drug ixekizumab for pityriasis rubra pilaris.<\/jats:p>\n                  <jats:p>What does this study add? \u00a0Herein we describe the findings of a clinical trial of secukinumab, an anti-IL-17A monoclonal antibody, for the treatment of pityriasis rubra pilaris.Secukinumab was effective in treating pityriasis rubra pilaris.Our transcriptomic data give new insight into the expressional changes that occur in response to secukinumab and suggest mechanisms of treatment resistance.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1111\/bjd.21708","type":"journal-article","created":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T02:54:40Z","timestamp":1655261680000},"page":"650-658","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Secukinumab for the treatment of adult-onset pityriasis rubra pilaris: a single-arm clinical trial with transcriptomic analysis"],"prefix":"10.1093","volume":"187","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4743-5530","authenticated-orcid":false,"given":"Blake W.","family":"Boudreaux","sequence":"first","affiliation":[{"name":"Department of Dermatology Mayo Clinic Arizona Scottsdale AZ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1722-5970","authenticated-orcid":false,"given":"Thais P.","family":"Pincelli","sequence":"additional","affiliation":[{"name":"Department of Dermatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0177-2996","authenticated-orcid":false,"given":"Puneet K.","family":"Bhullar","sequence":"additional","affiliation":[{"name":"Department of Dermatology Mayo Clinic Arizona Scottsdale AZ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8174-0382","authenticated-orcid":false,"given":"Meera H.","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Dermatology Mayo Clinic Arizona Scottsdale AZ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1477-7278","authenticated-orcid":false,"given":"Caitlin M.","family":"Brumfiel","sequence":"additional","affiliation":[{"name":"Department of Dermatology Mayo Clinic Arizona Scottsdale AZ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8541-8363","authenticated-orcid":false,"given":"Xing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Health Sciences Research, Division of Biomedical Statistics and Informatics Mayo Clinic Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3770-9331","authenticated-orcid":false,"given":"Michael G.","family":"Heckman","sequence":"additional","affiliation":[{"name":"Division of Biomedical Statistics and Informatics Mayo Clinic Jacksonville FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7913-0294","authenticated-orcid":false,"given":"Mark R.","family":"Pittelkow","sequence":"additional","affiliation":[{"name":"Department of Dermatology Mayo Clinic Arizona Scottsdale AZ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6873-1705","authenticated-orcid":false,"given":"Aaron R.","family":"Mangold","sequence":"additional","affiliation":[{"name":"Department of Dermatology Mayo Clinic Arizona Scottsdale AZ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7604-7073","authenticated-orcid":false,"given":"Jason C.","family":"Sluzevich","sequence":"additional","affiliation":[{"name":"Department of Dermatology"},{"name":"Department of Health Sciences Research, Division of Biomedical Statistics and Informatics Mayo Clinic Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,11,1]]},"reference":[{"key":"2023010808122007600_bjd21708-bib-0001","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2165\/11530070-000000000-00000","article-title":"Pityriasis rubra pilaris: a review of diagnosis and treatment","volume":"11","author":"Klein","year":"2010","journal-title":"Am J Clin Dermatol"},{"key":"2023010808122007600_bjd21708-bib-0002","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1001\/jamadermatol.2016.5384","article-title":"Interleukin 23\u2013helper T cell 17 axis as a treatment target for pityriasis rubra pilaris","volume":"153","author":"Feldmeyer","year":"2017","journal-title":"JAMA Dermatol"},{"key":"2023010808122007600_bjd21708-bib-0003","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1161\/ATVBAHA.114.304108","article-title":"Interleukin 17 drives vascular inflammation, endothelial dysfunction, and arterial hypertension in psoriasis-like skin disease","volume":"34","author":"Karbach","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2023010808122007600_bjd21708-bib-0004","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1111\/bjd.18263","article-title":"Rapid response of pityriasis rubra pilaris with psoriasis overlap to secukinumab","volume":"181","author":"Cole","year":"2019","journal-title":"Br J Dermatol"},{"key":"2023010808122007600_bjd21708-bib-0005","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/jamadermatol.2013.4773","article-title":"Treatment options for pityriasis rubra pilaris including biologic agents: a retrospective analysis from an academic medical center","volume":"150","author":"Eastham","year":"2014","journal-title":"JAMA Dermatol"},{"key":"2023010808122007600_bjd21708-bib-0006","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14097","article-title":"Secukinumab monotherapy successfully treated severe refractory type V (atypical juvenile) pityriasis rubra pilaris: a case report and literature review","volume":"33","author":"Liang","year":"2020","journal-title":"Dermatol Ther"},{"key":"2023010808122007600_bjd21708-bib-0007","first-page":"367","article-title":"Secukinumab emerges as a rapidly effective therapy for pityriasis rubra pilaris","volume":"101","author":"Bonomo","year":"2018","journal-title":"Cutis"},{"key":"2023010808122007600_bjd21708-bib-0008","first-page":"501","article-title":"Secukinumab is an effective and safe treatment for refractory pityriasis rubra pilaris","volume":"156","author":"Papini","year":"2021","journal-title":"Ital J Dermatol Venerol"},{"key":"2023010808122007600_bjd21708-bib-0009","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jdcr.2018.02.007","article-title":"Secukinumab in pityriasis rubra pilaris: a case series demonstrating variable response and the need for minimal clinical datasets","volume":"4","author":"Wain","year":"2018","journal-title":"JAAD Case Rep"},{"key":"2023010808122007600_bjd21708-bib-0010","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1001\/jamadermatol.2016.3885","article-title":"Successful treatment of refractory pityriasis rubra pilaris with secukinumab","volume":"152","author":"Schuster","year":"2016","journal-title":"JAMA Dermatol"},{"key":"2023010808122007600_bjd21708-bib-0011","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/ajd.13614","article-title":"A case of treatment-resistant pityriasis rubra pilaris responsive to secukinumab","volume":"62","author":"Simpson","year":"2021","journal-title":"Australas J Dermatol"},{"key":"2023010808122007600_bjd21708-bib-0012","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jdcr.2016.09.006","article-title":"Successful treatment of type II pityriasis rubra pilaris with secukinumab","volume":"2","author":"Gauci","year":"2016","journal-title":"JAAD Case Rep"},{"key":"2023010808122007600_bjd21708-bib-0013","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1093\/bioinformatics\/bts251","article-title":"DAVID-WS: a stateful web service to facilitate gene\/protein list analysis","volume":"28","author":"Jiao","year":"2012","journal-title":"Bioinformatics"},{"key":"2023010808122007600_bjd21708-bib-0014","doi-asserted-by":"crossref","first-page":"D325","DOI":"10.1093\/nar\/gkaa1113","article-title":"The Gene Ontology resource: enriching a GOld mine","volume":"49","author":"Gene Ontology Consortium","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"2023010808122007600_bjd21708-bib-0015","first-page":"25","article-title":"Gene ontology: tool for the unification of biology","volume":"25","author":"Ashburner","year":"2000","journal-title":"The Gene Ontology Consortium. Nat Genet"},{"key":"2023010808122007600_bjd21708-bib-0016","volume-title":"IL-17 signaling pathway \u2013 Homo sapiens (human)","author":"KEGG"},{"key":"2023010808122007600_bjd21708-bib-0017","author":"GeneCards \u2013 Human Gene Database"},{"key":"2023010808122007600_bjd21708-bib-0018","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/jid.2010.340","article-title":"Integrative responses to IL-17 and TNF-\u03b1 in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis","volume":"131","author":"Chiricozzi","year":"2011","journal-title":"J Invest Dermatol"},{"key":"2023010808122007600_bjd21708-bib-0019","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.coi.2007.04.005","article-title":"Differentiation and function of Th17 T cells","volume":"19","author":"Stockinger","year":"2007","journal-title":"Curr Opin Immunol"},{"key":"2023010808122007600_bjd21708-bib-0020","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.plipres.2012.10.003","article-title":"Bioactive lipid mediators in skin inflammation and immunity","volume":"52","author":"Kendall","year":"2013","journal-title":"Prog Lipid Res"},{"key":"2023010808122007600_bjd21708-bib-0021","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1038\/jid.2014.28","article-title":"Transcriptome analysis of psoriasis in a large case\u2013control sample: RNA-seq provides insights into disease mechanisms","volume":"134","author":"Li","year":"2014","journal-title":"J Invest Dermatol"},{"key":"2023010808122007600_bjd21708-bib-0022","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.151911","article-title":"Phospholipase A2 enzymes represent a shared pathogenic pathway in psoriasis and pityriasis rubra pilaris","volume":"6","author":"Shao","year":"2021","journal-title":"JCI Insight"},{"key":"2023010808122007600_bjd21708-bib-0023","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1084\/jem.20081463","article-title":"Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis","volume":"206","author":"Conti","year":"2009","journal-title":"J Exp Med"},{"key":"2023010808122007600_bjd21708-bib-0024","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1001\/jamadermatol.2020.0932","article-title":"Evaluation of ixekizumab treatment for patients with pityriasis rubra pilaris: a single-arm trial","volume":"156","author":"Haynes","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2023010808122007600_bjd21708-bib-0025","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1600-065X.2008.00628.x","article-title":"Th17 cells in human disease","volume":"223","author":"Tesmer","year":"2008","journal-title":"Immunol Rev"},{"key":"2023010808122007600_bjd21708-bib-0026","first-page":"597","article-title":"IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation","volume":"118","author":"Ma","year":"2008","journal-title":"J Clin Invest"},{"key":"2023010808122007600_bjd21708-bib-0027","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nri2586","article-title":"Structure and signalling in the IL-17 receptor family","volume":"9","author":"Gaffen","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"2023010808122007600_bjd21708-bib-0028","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.3390\/biom10101402","article-title":"cPLA2\u03b1 enzyme inhibition attenuates inflammation and keratinocyte proliferation","volume":"10","author":"Ashcroft","year":"2020","journal-title":"Biomolecules"},{"key":"2023010808122007600_bjd21708-bib-0029","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.bbalip.2018.08.009","article-title":"Small-molecule inhibitors as potential therapeutics and as tools to understand the role of phospholipases A2","volume":"1864","author":"Nikolaou","year":"2019","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"2023010808122007600_bjd21708-bib-0030","doi-asserted-by":"crossref","first-page":"244ra90","DOI":"10.1126\/scitranslmed.3008946","article-title":"Intraindividual genome expression analysis reveals a specific molecular signature of psoriasis and eczema","volume":"6","author":"Quaranta","year":"2014","journal-title":"Sci Transl Med"},{"key":"2023010808122007600_bjd21708-bib-0031","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1615\/CritRevImmunol.v37.i2-6.20","article-title":"Regulatory functions of phospholipase A2","volume":"37","author":"Murakami","year":"2017","journal-title":"Crit Rev Immunol"},{"key":"2023010808122007600_bjd21708-bib-0032","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14403","article-title":"Successful treatment of pityriasis rubra pilaris with guselkumab: serum CCL20 as a potential marker for the disease activity","volume":"33","author":"Nagai","year":"2020","journal-title":"Dermatol Ther"},{"key":"2023010808122007600_bjd21708-bib-0033","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jid.2021.06.009","article-title":"Pityriasis rubra pilaris response to IL-17A inhibition is associated with IL-17C and CCL20 protein levels","volume":"142","author":"Strunck","year":"2022","journal-title":"J Invest Dermatol"},{"key":"2023010808122007600_bjd21708-bib-0034","doi-asserted-by":"crossref","first-page":"15750","DOI":"10.1038\/s41598-018-34054-x","article-title":"The roles of IL-17C in T cell-dependent and -independent inflammatory diseases","volume":"8","author":"Yamaguchi","year":"2018","journal-title":"Sci Rep"},{"key":"2023010808122007600_bjd21708-bib-0035","doi-asserted-by":"crossref","first-page":"6740","DOI":"10.3390\/ijms22136740","article-title":"From messengers to receptors in psoriasis: the role of IL-17RA in disease and treatment","volume":"22","author":"Vidal","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2023010808122007600_bjd21708-bib-0036","doi-asserted-by":"crossref","first-page":"e249","DOI":"10.1111\/ajd.13215","article-title":"Successful treatment of pityriasis rubra pilaris with brodalumab","volume":"61","author":"De Rosa","year":"2020","journal-title":"Australas J Dermatol"},{"key":"2023010808122007600_bjd21708-bib-0037","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/ijd.14857","article-title":"Familial pityriasis rubra pilaris successfully treated with brodalumab","volume":"59","author":"De Felice","year":"2020","journal-title":"Int J Dermatol"},{"key":"2023010808122007600_bjd21708-bib-0038","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1111\/ijd.15219","article-title":"Response of pityriasis rubra pilaris to brodalumab after primary failure to ustekinumab","volume":"60","author":"Amat-Samaranch","year":"2021","journal-title":"Int J Dermatol"},{"key":"2023010808122007600_bjd21708-bib-0039","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/j.jid.2018.01.036","article-title":"Neutralization of IL-17C reduces skin inflammation in mouse models of psoriasis and atopic dermatitis","volume":"138","author":"Vandeghinste","year":"2018","journal-title":"J Invest Dermatol"},{"key":"2023010808122007600_bjd21708-bib-0040","author":"ClinicalTrials.gov"},{"key":"2023010808122007600_bjd21708-bib-0041","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/1346-8138.14709","article-title":"Case of pityriasis rubra pilaris progressed to generalized erythroderma following blockade of interleukin-17A, but improved after blockade of interleukin-12\/23 p40","volume":"46","author":"Matsuda","year":"2019","journal-title":"J Dermatol"},{"key":"2023010808122007600_bjd21708-bib-0042","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1111\/jdv.14128","article-title":"A randomized, double-blind, placebo-controlled, dose-escalation first-in-man study (phase 0) to assess the safety and efficacy of topical cytosolic phospholipase A2 inhibitor, AVX001, in patients with mild to moderate plaque psoriasis","volume":"31","author":"Omland","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023010808122007600_bjd21708-bib-0043","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.jaci.2010.12.1124","article-title":"Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities","volume":"127","author":"Su\u00e1rez-Fari\u00f1as","year":"2011","journal-title":"J Allergy Clin Immunol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjd.21708","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjd.21708","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/187\/5\/650\/48529805\/bjd0650.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/187\/5\/650\/48529805\/bjd0650.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T14:13:36Z","timestamp":1676384016000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/187\/5\/650\/6966429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,1]]},"references-count":43,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,11,1]]},"published-print":{"date-parts":[[2022,11,1]]}},"URL":"https:\/\/doi.org\/10.1111\/bjd.21708","relation":{},"ISSN":["1365-2133","0007-0963"],"issn-type":[{"value":"1365-2133","type":"electronic"},{"value":"0007-0963","type":"print"}],"subject":[],"published-other":{"date-parts":[[2022,11,1]]},"published":{"date-parts":[[2022,11,1]]},"assertion":[{"value":"2022-02-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}